Sitemap
- Startpagina
- Neurologie
- Dermatologie
- Atopisch Eczeem
- Artikelen
- Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)
- Long-Term Efficacy and Safety of Dupixent in Moderate-to-Severe Atopic Dermatitis: 5-Year Open-Label Extension Study Results1
- Publicaties op basis van Nederlandse RWE veiligheids- en effectiviteitsdata in de behandeling van atopisch eczeem
- Hulpmiddelen
- Events
- Educatie
- DermTalks Podcasts – Atopic Dermatitis in Special Populations
- Managing Atopic Dermatitis in Patients with Comorbidities
- Managing Pediatric Atopic Dermatitis
- Webinarserie - DermaDialogen
- Webinar - Van data naar doen!
- Atopic Dermatitis in Melanin-Rich Skin – A DermTalks Webinar
- Introduction to hand and foot dermatitis
- Podcast - Constitutioneel eczeem door dermatologen Marjolein de Bruin-Weller en Marlies de Graaf
- Hot topics in atopic dermatitis: Longterm Control in AD
- Hot topics in atopic dermatitis: Hear it from the experts
- Managing Atopic Dermatitis in the Elderly
- Managing Atopic Dermatitis During Pregnancy and Breastfeeding
- Artikelen
- Atopisch Eczeem bij kinderen
- Prurigo Nodularis
- Atopisch Eczeem
- Diabetes
- Diabetes type 2
- Artikelen
- Switching from other basal insulins to Toujeo® (Insulin Glargine)
- How Does Glycaemic Control Impact Complications in Type 2 Diabetes?
- Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?
- When to Initiate Basal Insulin?
- Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?
- Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?
- Hulpmiddelen
- Events
- Educatie
- Artikelen
- Diabetes type 1
- Diabetes type 2
- Zeldzame Ziekten
- Zeldzame Bloedziekten
- Respiratoire aandoeningen
- Cardiologie
- Dyslipidemie
- Artikelen
- PRALUENT is available as a unique, once-monthly pen
- 146 for Lipid Management After ACS
- Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control
- What is PRALUENT®?
- Why choose PRALUENT®?
- Cardiovascular diseases (CVDs) are the leading cause of death globally
- 2024 ESC Guidelines for the management of chronic coronary syndromes
- Approach for patients with coronary artery disease (CAD): focus on LDL-C control
- Educatie
- Preventive Cardiology: Key Insights from Professor Michal Vrablik
- Why Don’t We Strike Early, Strike Strong?
- A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
- Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi
- Artikelen
- Dyslipidemie
- Vaccins
- Andere onderwerpen
- Type 2 Inflammatie
- Producten
- Therapeutische gebieden
- Sitemap
- Registreren
- Log in
- Gebruiksvoorwaarden
- Data Privacy
- Cookieverklaring